Volume 28, Number 4—April 2022
Dispatch
Bordetella hinzii Pneumonia in Patient with SARS-CoV-2 Infection
, José Bras Cachinho, Pierre Kalfon, Thierry Naas, and Zehaira Benseddik
Table
Antimicrobial susceptibility of Bordetella hinzii isolate from patient with pneumonia and severe respiratory syndrome coronavirus 2 infection, by Etest and broth microdilution*
| Test and antimicrobial drug |
MIC for Etest, μg/mL |
MIC for BMD, μg/mL |
Interpretation |
EUCAST PK-PD breakpoint, mg/L† |
|
|---|---|---|---|---|---|
| S |
R |
||||
| Routine antibiogram | |||||
| Amoxicillin | 32 | ND | R | <2 | >8 |
| Amoxicillin/clavulanic acid (2)‡ | 6 | ND | I | <2 | >8 |
| Ticarcillin/clavulanic acid | 16 | ND | I | <8 | >16 |
| Piperacillin/tazobactam (4)‡ | 0.5§ | <4 | S | <8 | >16 |
| Cefotaxim | >32 | ND | R | <1 | >2 |
| Ceftazidime | 2 | ND | S | <4 | >8 |
| Aztreonam | >256 | >32 | R | <4 | >8 |
| Cefepime | 4 | 4 | S | <4 | >8 |
| Meropenem | 0.06 | 0.25 | S | <2 | >8 |
| Imipenem | 0.75 | <1 | S | <2 | >4 |
| Ciprofloxacin | 0.75 | ND | R | <0.25 | >0.5 |
| Levofloxacin | 0.75 | ND | I | <0.5 | >1 |
| Amikacin | 8 | 2 | R | <1 | >1 |
| Gentamicin | 2 | ND | R | <0.5 | >0.5 |
| Tobramycin |
8 |
>4 |
R |
<0.5 |
>0.5 |
| Additional antimicrobial drugs tested | |||||
| Imipenem/relebactam (4)‡ | ND | 1 | S | <2 | >2 |
| Meropenem/vaborbactam (8)‡ | ND | 0.12 | S | <8 | >8 |
| Ceftazidime/avibactam (4)‡ | ND | 4 | S | <8 | >8 |
| Cefiderocol | ND | 1 | S | <2 | >2 |
| Ceftolozane/tazobactam (4)‡ | ND | 8 | R | <4 | >4 |
| Tigecycline | ND | 0.5 | S | 0.5 | >0.5 |
| Eravacycline | ND | 0.12 | IE | IE | IE |
| Fosfomycin | ND | >64 | IE | IE | IE |
| Colistin | ND | <0.5 | IE | IE | IE |
*BMD, broth microdilution; EUCAST, European Committee on Antimicrobial Susceptibility Testing; I, intermediate/susceptible with high dose; IC, inhibitory concentration; IE, insufficient evidence; ND, not determined; PK/PD, pharmacokinetic/pharmacodynamic; R, resistant; S, susceptible. †MIC breakpoints were interpreted by using EUCAST guidelines and PK-PD (nonspecies related) breakpoints (https://www.eucast.org/clinical_breakpoints). ‡Numbers in parentheses indicate the amount of inhibitor used: 2 μg/mL for clavulanic acid; 4 μg/mL for tazobactam, relebactam, and avibactam; and 8 μg/mL for vaborbactam. §Piperacillin/tazobactam MIC was determined by using the PIP/Tazo UMIC strip (Biocentric, https://biocentricinc.com).